Navigation Links
Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
Date:6/21/2013

Irvine, CA (PRWEB) June 21, 2013

Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, today announced that its current investor group, including its newest investor Partners & Partners, has funded the third $10 million tranche that rounds out the total financing of $30 million initiated in December 2011. This financing was again triggered by the company’s successful achievement of revenue milestones ahead of schedule.

The proceeds will be used to build out commercial infrastructure, accelerate the nationwide commercial launch, broaden third-party reimbursement and initiate foreign distribution of MIRISK VP™, Aviir’s proprietary cardiac risk assessment technology, and additional laboratory testing services. Merck Global Health Innovation Fund led the round, and was joined by Partners & Partners. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.

Douglas Harrington, M.D., CEO of Aviir commented, “Our pilot and regional launch programs have generated both enthusiastic response among the physician community and commercial adoption. The additional funding will now allow us to conduct a more broad commercial launch domestically and take the next steps toward a comprehensive international distribution plan to be rolled out later this year.”

Harrington continued, “The MIRISK test determines an individual’s risk of experiencing future cardiac events, enabling them to take preventive action before it is too late. 50% of people who have a heart attack have normal cholesterol levels, but cholesterol is only part of the risk equation. More than 70% of heart attacks are caused by the rupture of unstable plaque in the arteries, which leads to clotting and heart attacks. The MIRISK test serves as an early warning system that this condition may be present and, importantly, can be addressed.
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. Aviir Laboratories Announce National Agreement With MultiPlan
3. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
4. Aviir Laboratories Announce National Agreement with Stratose
5. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
6. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
7. Aviir Sponsors Eco Hideaway 2013 Music Artist Stage At The Chateaux In Park City, Utah To Benefit Heart Disease
8. Aviir Signs Distribution and Expansion Pact Covering 19 Middle Eastern and North African Countries
9. Aviir Signs Distribution And Expansion Pact Covering 19 Middle Eastern And North African Countries
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... MedPredict Market Research,a global provider of ... a new report providing critical strategic insight,for ... in the market for MS,therapies. In ... & Analysis:,Multiple Sclerosis," physician experts discuss the ...
... Business Update - ... Time -, OAKLAND, Calif., Nov. 14 World Heart,Corporation ... circulatory,support systems, will report its third quarter 2007 financial results ... in a,teleconference at 8:30 a.m. Pacific / 11:30 a.m. Eastern ...
... Following the Screening and the Testing of Hundreds ... Reduce Liver Cancer Cell Growth, REHOVOT, Israel ... Genomics, Ltd. (NASDQ: ROSG) announced,today the initiation of ... program conducted in collaboration with Isis Pharmaceuticals(1),(NASDAQ: ...
Cached Biology Technology:New Report Analyzes Key Controversies in Multiple Sclerosis Treatment 2Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer 2Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer 3Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer 4
(Date:8/11/2015)... Sweden , August 11, 2015 Today, ... FPC1155. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... in Madagascar regularly retire to limestone chambers for their ... use of the same caves and crevices for sleeping ... lemurs may be opting to sleep in caves for ... Professor Michelle Sauther, who led the study. While the ...
... 4, 2013 A team of Montral researchers at the ... Dr. William C. Wetsel,s team at Duke University in the ... role in the brain by affecting certain types of cognitive ... recently published in the scientific journals Proceedings of the ...
... 4, 2013 Elsevier, EuroStemCell, and Kyoto University,s Institute ... Research report: Trends and Perspectives on the Evolving International ... comprehensive analysis of the growth and development of the ... research landscape for embryonic stem (ES) cell, human embryonic ...
Cached Biology News:CU-Boulder-led team finds first evidence of primates regularly sleeping in caves 2CU-Boulder-led team finds first evidence of primates regularly sleeping in caves 3CU-Boulder-led team finds first evidence of primates regularly sleeping in caves 4An important discovery related to anxiety disorders and trauma 2An important discovery related to anxiety disorders and trauma 3New report on stem cell research reveals the field is growing twice as fast as the world average 2New report on stem cell research reveals the field is growing twice as fast as the world average 3
... Western Protein Array was developed using a ... Arrays are manufactured using high quality denatured ... protein sample from each of 30 tissues ... molecular weight marker on a large size ...
... Microarrays Using the New FAST(tm) Frame Multi-Slide ... is designed to hold four, 16-pad FAST ... in a microplate footprint for high throughput ... the standards recommended by the Society of ...
... 2D Multi-User Applications Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... both proteomic and general life science research ... the use of all dyes in the ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: